期刊
ANESTHESIA AND ANALGESIA
卷 110, 期 2, 页码 524-525出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1213/ANE.0b013e3181c5f069
关键词
-
资金
- institutional and departmental sources
Remifentanil is a potent mu-opioid receptor agonist that produces intense analgesia. This anilidopiperidine analog of fentanyl was approved by the United States Food and Drug Administration and became commercially available in the United States in 1997. Because of its unique chemical structure, remifentanil must be reconstituted; it has a rapid onset, and because of ester hydrolysis, it has a rapid rate of degradation. Although remifentanil's package insert warns against the potential for addiction, because of its rapid rate of degradation there was little concern that health care workers would abuse this drug. Herein, we report a case of intranasal remifentanil abuse by an anesthesiology resident. (Anesth Analg 2010;110:524-5)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据